Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $76 (market cap $2.02B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.7× Global X Robo Global Robotics & Automation ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 38 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ROBO | SYRE | |
|---|---|---|
Market Cap | $2.02B | $7.52B |
Volume | 103,334 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $108.92 |
52-Week Low | $63.04 | $22.18 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.85, down 0.22% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The robotics ETF faces mixed sentiment amid AI-driven sector growth but lacks current fundamental data for valuation metrics. Recent news highlights robotics adoption expanding beyond automotive into manufacturing, healthcare, and military applications, though earnings visibility remains limited for underlying holdings.
The outlook for ROBO hinges on broader AI and robotics adoption trends, with potential from labor shortages and military demand, but risks include valuation concerns in tech and cyclical exposure. Investors should monitor earnings from constituent companies for fundamental validation of growth narratives amid neutral oscillator signals and bearish technical momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
